The Potential Role of Psychedelic Drugs in Mental Health Care of the Future
This review (2021) summarizes the challenges for creating a new treatment infrastructure for Psychedelic-assisted psychotherapy in the process of re-contextualizing psychopharmacological interventions within a paradigm that lays particular emphasis on preparation, integration, and the development of structured patient communities as crucial components of therapy.
Authors
- Henrik Jungaberle
- Gerhard Gründer
Published
Abstract
Serotonergic psychedelics such as psilocybin, lysergic acid diethylamide (LSD), or dimethyltryptamine (DMT), as well as psychoactive drugs that trigger phenomenologically- related experiences like 3,4-methylenedioxymethamphetamine (MDMA) and ketamine, belong to the most promising treatment approaches in contemporary psychiatry. Psychedelic-assisted psychotherapy is not only a new treatment paradigm in psychopharmacology, but it also requires a redefinition of psychotherapeutic processes and the contextualization of psychopharmacological interventions within a new treatment infrastructure. Crucial for future practice and research in the field are (1) informed patient referral and co-treatment practices, (2) screening (e. g., choosing the right patients for these therapies), (3) the dosing preparation sessions, (4) the assisted dosing sessions as well as after-care procedures such as (5) psychological integration and (6) supporting the development of structured patient communities. Definition of future treatment delivery infrastructures and requirements for therapist training are further challenges for research and practice. Finally, the implementation of psychedelic-assisted psychotherapy in routine mental health care must be embedded into public communication about the potential and risks of these innovative therapeutic approaches. This paper provides a synopsis of challenges for practitioners, researchers, and regulators to be addressed in the approval processes of psychedelics.
Research Summary of 'The Potential Role of Psychedelic Drugs in Mental Health Care of the Future'
Introduction
Psychedelic drugs that produce profound alterations in perception, emotion and self-awareness—classical compounds such as LSD, psilocybin and DMT, alongside substances that evoke phenomenologically similar states like MDMA and ketamine—have re-emerged as a promising area in psychiatry after decades of prohibition. Gründer and Jungaberle situate these agents within a broader challenge to prevailing psychopharmacological paradigms: unlike standard daily-administered psychotropics, many psychedelic interventions appear to produce rapid and sometimes sustained clinical benefit after only one or a few supervised administrations, suggesting a different model of drug–psychotherapy interaction. This paper sets out to review the current scientific status of psychedelic therapies and to outline practical and regulatory challenges for integrating them into routine mental health care. Gründer and Jungaberle aim to synthesise historical context, findings from Phase I–III studies, and implementation considerations (training, screening, treatment delivery, after‑care and public communication) to inform practitioners, researchers and regulators about key issues that must be addressed as these treatments move toward clinical approval and wider use.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typemeta
- Journal
- Compound
- Authors
- APA Citation
Gründer, G., & Jungaberle, H. (2021). The Potential Role of Psychedelic Drugs in Mental Health Care of the Future. Pharmacopsychiatry, 54(04), 191-199. https://doi.org/10.1055/a-1486-7386
References (36)
Papers cited by this study that are also in Blossom
Mithoefer, M. C., Feduccia, A. A., Jerome, L. et al. · Psychopharmacology (2019)
Nichols, D. E., Walter, H. · Pharmacopsychiatry (2020)
Nayak, S., Johnson, M. W. · Pharmacopsychiatry (2020)
Vollenweider, F. X., Leenders, K. L., Maguire, P. et al. · Neuropsychopharmacology (1997)
Madsen, M. K., Fisher, P. M., Burmester, D. et al. · Neuropsychopharmacology (2019)
Mertens, L. J., Preller, K. H. · Pharmacopsychiatry (2021)
Hartogsohn, I. · Drug Science Policy and Law (2017)
Carhart-Harris, R. L., Roseman, L., Haijen, E. C. H. M. et al. · Journal of Psychopharmacology (2018)
Vollenweider, F. X., Preller, K. H. · Nature Reviews Neuroscience (2020)
Olson, D. E. · ACS Pharmacology and Translational Science (2020)
Show all 36 referencesShow fewer
Yaden, D. B., Griffiths, R. R. · ACS Pharmacology and Translational Science (2020)
Swanson, L. R. · Frontiers in Pharmacology (2018)
Richards, W. A., Garcia-Romeu, A. · International Review of Psychiatry (2018)
Trope, A., Anderson, B. T., Hooker, A. R. et al. · Journal of Psychoactive Drugs (2019)
Hutten, N. R. P. W., Mason, N. L., Dolder, P. C. et al. · European Neuropsychopharmacology (2020)
Lea, T., Jungaberle, H., Schecke, H. et al. · Psychopharmacology (2020)
Kaertner, L. S., Steinborn, M. B., Kettner, H. et al. · Scientific Reports (2021)
Carhart-Harris, R. L. · Current Opinion in Psychiatry (2019)
Gasser, P., Holstein, D., Michel, Y. et al. · Journal of Nervous and Mental Disease (2014)
Liechti, M. E. · Neuropsychopharmacology (2017)
Belser, A. B., Agin-Liebes, G. I., Swift, T. C. et al. · Journal of Humanistic Psychology (2017)
Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Psychopharmacology (2011)
Millière, R. · Frontiers in Human Neuroscience (2017)
Phelps, J. · Journal of Humanistic Psychology (2017)
Nielson, E. M., Guss, J. · Journal of Psychedelic Studies (2018)
Luoma, J. B., Sabucedo, P., Eriksson, J. et al. · Journal of Contextual Behavioral Science (2019)
Jungaberle, H., Thal, S., Zeuch, A. et al. · Neuropharmacology (2018)
Aday, J. S., Davoli, C. C., Bloesch, E. K. · Therapeutic Advances in Psychopharmacology (2020)
Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K. et al. · Neuroscience and Biobehavioral Reviews (2020)
Johnson, M. W., Garcia-Romeu, A., Griffiths, R. R. · The American Journal of Drug and Alcohol Abuse (2016)
Breeksema, J. J., Niemeijer, A. R., Krediet, E. et al. · CNS Drugs (2020)
Roseman, L., Haijen, E. C. H. M., Idialu-Ikato, K. et al. · Journal of Psychopharmacology (2019)
Carhart-Harris, R. L., Leech, R., Williams, T. M. et al. · British Journal of Psychiatry (2018)
Bouso, J. C., Dos Santos, R. G., Hallak, J. E. · Neuroscience and Biobehavioral Reviews (2018)
Maclean, K. A., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2011)
Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)
Cited By (4)
Papers in Blossom that reference this study
Gründer, G., Brand, M., Mertens, L. J. et al. · Lancet Psychiatry (2024)
Hipólito, I., Mago, J., Rosas, F. E. et al. · Psyarxiv (2022)
Mertens, L. J., Koslowski, M., Betzler, F. et al. · Neuroscience Applied (2022)
Williams, M. L., Korevaar, D., Harvey, R. et al. · Frontiers in Psychiatry (2021)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.